Navigation Links
VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
Date:5/25/2011

nal study report will be submitted to the FDA upon completion.  VIVUS expects to file the NDA for avanafil in the second quarter of 2011.

About the StudyTA-303 was a randomized, double-blind, placebo-controlled, parallel group, multicenter study of the safety and efficacy of avanafil in the treatment of erectile dysfunction following bilateral, nerve-sparing, radical prostatectomy in 298 men with ED.  On average, subjects entering the study were 58 years old, 19 months past their surgery dates and diagnosed with severe ED.  Subjects were randomized to 100mg or 200mg avanafil or placebo and were instructed to take one dose of study drug 30 minutes prior to initiation of sexual activity.  The study had a four-week run-in period followed by 12 weeks of treatment.  The primary endpoints of the study were improvement in erectile function as measured by the SEP2 and SEP3 and improvements in the EF-Domain of the IIEF score; secondary endpoints included patient satisfaction with erections and with sexual experience.

About the Avanafil Phase 3 ProgramIn addition to TA-303, the avanafil phase 3 program consists of three pivotal studies:  TA-301 (REVIVE), TA-302 (REVIVE-Diabetes), and TA-314. TA-301 and TA-302 were randomized, double-blind, placebo-controlled phase 3 studies of avanafil in 646 and 390 men, respectively, with a history of ED for at least six months. Each of these trials had a similar trial design with patients undergoing a four-week, non-treatment run-in period followed by 12 weeks of treatment. Primary endpoints of the studies are improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the EF Domain score of the International Index of Erectile Function (IIEF). In both the TA-301 and TA-302 studies, all doses of avanafil met the primary endpoints, with successful intercourse achieved by some subjects as early as 15 minutes after dosing. TA-314 was an open
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
11. VIVUS to Present at the 10th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... for advanced fluid applications and designed for continuous operation up to 1500 bar. ... sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... 2010 AVANIR Pharmaceuticals, Inc. (Nasdaq: ... offer and sell shares of its common stock in an ... sole book-running manager in the offering and Canaccord Genuity Inc., ... Capital are acting as co-managers for the offering.  In addition ...
... a leading Clinical Research Organization, announces that the head ... speak at the 3rd annual China Drug Safety and ... 2010. Dr. Sabine Richter, PRA,s Vice President ... "Challenges of Drug Safety in Global Clinical Trials." Her ...
... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
Cached Biology Technology:AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock 2PRA International Expert to Speak at China Drug Safety Summit 2Enerkem adds two new executive roles to growing North American presence 2Enerkem adds two new executive roles to growing North American presence 3Enerkem adds two new executive roles to growing North American presence 4Enerkem adds two new executive roles to growing North American presence 5Enerkem adds two new executive roles to growing North American presence 6Enerkem adds two new executive roles to growing North American presence 7
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... understanding the basis of coral reef recovery, researchers have ... pinnatus, in promoting the return to health of a ... to light a previously unrecognized role for the batfish ... in reef recovery after overfishing. In doing so, the ...
... developed a new method to identify the "DNA-binding transcription factors" ... of cells that ultimately make up all the organs and ... were made using mouse embryonic spinal cord as a model, ... National Academy of Sciences, a professional journal. , The ...
... have discovered why the aging brain produces progressively ... memory center. The scientists said the finding, made ... crucial "progenitor" stem cells persist in the aging ... of treating various neurodegenerative disorders, including Alzheimer's disease, ...
Cached Biology News:Fish species plays surprise role in aiding coral reef recovery 2Advance helps explain stem cell behavior 2Advance helps explain stem cell behavior 3Stem cell activity deciphered in the aging brain 2
mCD-1 10 transcription reactions...
... x 2 , Maintenance 112 ... , Immunizations/Boost injections x5 /each ... x1 /each , Production bleed (25 ... Final Bleed ~ 100 ml blood (~50 ml serum) ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
Biology Products: